Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Director | June 08, 2023 | June 12, 2023 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 14, 2023 | June 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entrada Therapeutics, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.67 · Expires 2033-06-08 | Direct | 16,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 16,000 · Balance 16,000 F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders.
Intellia Therapeutics, Inc.
Report date June 14, 2023 · Filed June 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,716 |
Reported balance
After 2023-06-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 4,425 · Balance 11,716 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.20 · Expires 2033-06-13 | Direct | 6,473 |
Reported balance
After 2023-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-14 · Grant · Acquired 6,473 · Balance 6,473 F2: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date January 09, 2024 · Filed March 15, 2024 · Amendment
Section 16 reporting ended · disclosed 2024-03-15. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 927,013 |
Last balance in matching sequence
After 2024-01-10 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2024-01-09 · Grant · Acquired 57,620 · Balance 995,492 F1: Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors. F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Row 2 · 2024-01-09 · Tax withholding · Disposed 36,865 · Balance 958,627 F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Row 3 · 2024-01-10 · Sale · Disposed 31,614 · Balance 927,013 F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors.
F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly.
F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2019 Filed Aug 2, 2019 20:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001209191-19-044274 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,439 Underlying: Common Stock · 20,000 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options were fully vested and exercisable as of August 1, 2019. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 20:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $12.54 | $250,736.00 |
DisclosureSEC source: 0001209191-19-044274 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,194 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.37 to $12.74 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 20:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $3.82 | $76,400.00 |
DisclosureSEC source: 0001209191-19-044274 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 770,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:18 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001209191-19-040465 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,439 Underlying: Common Stock · 20,000 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options were fully vested and exercisable as of July 1, 2019. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:18 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $12.47 | $249,462.00 |
DisclosureSEC source: 0001209191-19-040465 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,194 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.36 to $12.68 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:18 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $3.82 | $76,400.00 |
DisclosureSEC source: 0001209191-19-040465 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 770,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 01:17 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 205 | $11.35 | $2,326.75 |
DisclosureSEC source: 0001209191-19-037870 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,194 Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 20:34 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001209191-19-034294 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,439 Underlying: Common Stock · 20,000 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options were fully vested and exercisable as of June 3, 2019. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 20:34 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $11.15 | $223,072.00 |
DisclosureSEC source: 0001209191-19-034294 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,399 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.97 to $11.38 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 20:34 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $3.82 | $76,400.00 |
DisclosureSEC source: 0001209191-19-034294 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 770,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:22 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001209191-19-026995 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,439 Underlying: Common Stock · 20,000 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options were fully vested and exercisable as of May 1, 2019. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:22 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $13.51 | $270,154.00 |
DisclosureSEC source: 0001209191-19-026995 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,399 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.26 to $13.70 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:22 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $3.82 | $76,400.00 |
DisclosureSEC source: 0001209191-19-026995 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 770,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 11, 2019 Filed Apr 15, 2019 23:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 82,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-024655 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,399 F1 · security: Granted in the form of Restricted Stock Units for the achievement of the 2017 PRSU clinical goal. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock. The Restricted Stock Units will vest on December 31, 2019, subject to the reporting person's continued service with the Company. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:29 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 9,791 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001209191-19-023453 · doc4.xml · derivative · entry 6 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,439 Underlying: Common Stock · 9,791 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options were fully vested and exercisable as of April 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:29 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 10,209 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-19-023453 · doc4.xml · derivative · entry 5 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,209 shares Expires 2024-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options were fully vested and exercisable as of April 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:29 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $13.63 | $272,626.00 |
DisclosureSEC source: 0001209191-19-023453 · doc4.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,081 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.43 to $13.95. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:29 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 9,791 | $3.82 | $37,401.62 |
DisclosureSEC source: 0001209191-19-023453 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 688,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:29 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 10,209 | $3.19 | $32,566.71 |
DisclosureSEC source: 0001209191-19-023453 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 678,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:47 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 467 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001209191-19-016822 · doc4.xml · derivative · entry 9 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 467 shares Expires 2022-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the options were fully vested and exercisable as of March 1, 2019 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:47 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 8,770 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001209191-19-016822 · doc4.xml · derivative · entry 8 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,770 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the options were fully vested and exercisable as of March 1, 2019 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:47 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 10,763 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-19-016822 · doc4.xml · derivative · entry 7 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,209 Underlying: Common Stock · 10,763 shares Expires 2024-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the options were fully vested and exercisable as of March 1, 2019 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:47 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 15,382 | $13.79 | $212,080.86 |
DisclosureSEC source: 0001209191-19-016822 · doc4.xml · nonDerivative · entry 5 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,081 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. F3 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.38 to $13.99. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:47 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 4,618 | $12.97 | $59,898.23 |
DisclosureSEC source: 0001209191-19-016822 · doc4.xml · nonDerivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 683,463 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.34 to $13.31. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:47 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 467 | $6.45 | $3,012.15 |
DisclosureSEC source: 0001209191-19-016822 · doc4.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 688,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:47 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 8,770 | $3.82 | $33,501.40 |
DisclosureSEC source: 0001209191-19-016822 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:47 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 10,763 | $3.19 | $34,333.97 |
DisclosureSEC source: 0001209191-19-016822 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 678,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:10 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001209191-19-007478 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 20,000 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options were fully vested and exercisable as of February 1, 2019. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:10 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $12.12 | $242,320.00 |
DisclosureSEC source: 0001209191-19-007478 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,081 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.96 to $12.41. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:10 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $3.82 | $76,400.00 |
DisclosureSEC source: 0001209191-19-007478 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 688,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 01:47 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 103,500 | $0.00 Strike: $10.36 | $0.00 |
DisclosureSEC source: 0001209191-19-004447 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,500 shares Expires 2019-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options were fully vested and exercisable as of January 15, 2019. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 01:47 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 103,500 | $11.71 | $1,212,295.50 |
DisclosureSEC source: 0001209191-19-004447 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,081 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.36 to $11.97. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 01:47 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 103,500 | $10.36 | $1,072,260.00 |
DisclosureSEC source: 0001209191-19-004447 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2019 Filed Jan 10, 2019 23:00 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 358,126 | $0.00 Strike: $10.04 | $0.00 |
DisclosureSEC source: 0001209191-19-003308 · doc4.xml · derivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,126 Underlying: Common Stock · 358,126 shares Expires 2029-01-02 F3 · derivative.exercise_date: These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on the first anniversary of the grant date. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments beginning on the first month thereafter. Read SEC document |
| January 02, 2019 Filed Jan 10, 2019 23:00 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 233,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-003308 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,081 F1 · security: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock. F2 · shares: The Restricted Stock Units will vest in four equal annual installments beginning on January 2, 2020. F1 · price: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 23:14 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 154,076 | $0.00 Strike: $15.67 | $0.00 |
DisclosureSEC source: 0001209191-18-002537 · doc4.xml · derivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,076 Underlying: Common Stock · 154,076 shares Expires 2028-01-03 F1 · derivative.exercise_date: These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on January 3, 2019. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on February 1, 2019, with the final installment vesting on January 1, 2022. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 23:14 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 106,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-002537 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,604 Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:00 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 5,920 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-18-000343 · doc4.xml · derivative · entry 7 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,538 Underlying: Common Stock · 5,920 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:00 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 5,920 | $14.75 | $87,320.00 |
DisclosureSEC source: 0001209191-18-000343 · doc4.xml · nonDerivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F5 · price: This price of $14.75 is the sole sale price for the transactions reported on this line. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:00 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 5,920 | $14.75 | $87,320.00 |
DisclosureSEC source: 0001209191-18-000343 · doc4.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F4 · price: This price of $14.75 is the sole purchase price for the transactions reported on this line. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 23:00 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 13,050 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-18-000343 · doc4.xml · derivative · entry 6 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,458 Underlying: Common Stock · 13,050 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 23:00 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 13,050 | $14.75 | $192,496.64 |
DisclosureSEC source: 0001209191-18-000343 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F3 · price: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.76. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 23:00 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 13,050 | $14.75 | $192,496.64 |
DisclosureSEC source: 0001209191-18-000343 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F2 · price: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.76. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 21, 2017 Filed Dec 21, 2017 22:19 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 506 | $0.00 Strike: $10.21 | $0.00 |
DisclosureSEC source: 0001209191-17-066833 · doc4.xml · derivative · entry 7 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 506 shares Expires 2018-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| December 21, 2017 Filed Dec 21, 2017 22:19 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 506 | $13.51 | $6,835.55 |
DisclosureSEC source: 0001209191-17-066833 · doc4.xml · nonDerivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F5 · price: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.50 to $13.52. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 21, 2017 Filed Dec 21, 2017 22:19 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 506 | $13.51 | $6,835.55 |
DisclosureSEC source: 0001209191-17-066833 · doc4.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F4 · price: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.50 to $13.52. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:19 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 65,075 | $0.00 Strike: $10.21 | $0.00 |
DisclosureSEC source: 0001209191-17-066833 · doc4.xml · derivative · entry 6 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506 Underlying: Common Stock · 65,075 shares Expires 2018-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:19 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 65,075 | $13.51 | $878,928.98 |
DisclosureSEC source: 0001209191-17-066833 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,001 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F3 · price: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.50 to $13.54. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:19 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 65,075 | $13.51 | $878,928.98 |
DisclosureSEC source: 0001209191-17-066833 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F2 · price: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.50 to $13.54. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 22:13 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 6,991 | $0.00 Strike: $10.21 | $0.00 |
DisclosureSEC source: 0001209191-17-065483 · doc4.xml · derivative · entry 5 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,581 Underlying: Common Stock · 6,991 shares Expires 2018-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.